ICU Medical (NASDAQ:ICUI) Upgraded to “Strong-Buy” at Raymond James

Raymond James upgraded shares of ICU Medical (NASDAQ:ICUI) from an outperform rating to a strong-buy rating in a research report report published on Wednesday morning, MarketBeat Ratings reports. They currently have $197.00 target price on the medical instruments supplier’s stock, down from their previous target price of $205.00.

ICUI has been the subject of several other research reports. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a research note on Wednesday, December 11th. StockNews.com downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Monday, March 10th. Finally, KeyCorp lifted their price target on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ICU Medical has an average rating of “Moderate Buy” and a consensus target price of $168.67.

ICU Medical Stock Performance

ICUI opened at $143.45 on Wednesday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical has a 12-month low of $93.36 and a 12-month high of $196.26. The firm has a 50 day moving average of $157.61 and a two-hundred day moving average of $165.08. The firm has a market capitalization of $3.52 billion, a PE ratio of -31.39 and a beta of 0.73.

Insiders Place Their Bets

In other news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC increased its holdings in ICU Medical by 15.6% in the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after acquiring an additional 8,010 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of ICU Medical in the third quarter valued at about $3,884,000. Principal Financial Group Inc. increased its stake in shares of ICU Medical by 24.6% during the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock worth $23,130,000 after purchasing an additional 25,031 shares in the last quarter. MetLife Investment Management LLC raised its position in shares of ICU Medical by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock worth $2,258,000 after purchasing an additional 6,981 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in ICU Medical in the 4th quarter valued at about $556,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.